Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Forte Biosciences SG&A Expense (TTM) : 10.25M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.25M |
| March 31, 2026 | 10.95M |
| December 31, 2025 | 12.41M |
| September 30, 2025 | 11.70M |
| June 30, 2025 | 11.27M |
| March 31, 2025 | 15.39M |
| December 31, 2024 | 15.41M |
| September 30, 2024 | 16.10M |
| June 30, 2024 | 17.19M |
| March 31, 2024 | 12.01M |
| December 31, 2023 | 10.62M |
| September 30, 2023 | 10.26M |
| June 30, 2023 | 8.458M |
| March 31, 2023 | 8.549M |
| December 31, 2022 | 8.302M |
| September 30, 2022 | 7.798M |
| June 30, 2022 | 7.797M |
| March 31, 2022 | 8.035M |
| December 31, 2021 | 7.633M |
| September 30, 2021 | 7.154M |
| Date | Value |
|---|---|
| June 30, 2021 | 6.431M |
| March 31, 2021 | 4.967M |
| December 31, 2020 | 4.221M |
| September 30, 2020 | 3.159M |
| June 30, 2020 | 2.17M |
| March 31, 2020 | 1.729M |
| December 31, 2019 | 5.502M |
| September 30, 2019 | 8.594M |
| June 30, 2019 | 12.58M |
| March 31, 2019 | 14.84M |
| December 31, 2018 | 12.81M |
| September 30, 2018 | 11.72M |
| June 30, 2018 | 9.579M |
| March 31, 2018 | 9.036M |
| December 31, 2017 | 8.557M |
| September 30, 2017 | 6.154M |
| June 30, 2017 | 5.081M |
| March 31, 2017 | 3.051M |
| June 30, 2016 | 1.111M |
| March 31, 2016 | 1.111M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| argenx SE | 1.537B |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |
| Savara, Inc. | 56.71M |